Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Neoplasm
89%
Overall Survival
77%
Malignant Neoplasm
75%
Melanoma
65%
Immunotherapy
57%
Radiation Therapy
50%
Diseases
45%
Cancer
44%
Urothelial Cancer
41%
Metastatic Carcinoma
39%
Multiple Myeloma
36%
Disease
35%
Ipilimumab
32%
Metastatic Melanoma
32%
Meta-Analysis
31%
Pembrolizumab
31%
Nodular Melanoma
29%
Infection
29%
Hazard Ratio
28%
Bladder Cancer
27%
Treatment Response
24%
Oncology
24%
Transitional Cell Carcinoma
23%
Infusion
22%
Systematic Review
22%
Acute Myeloid Leukemia
20%
Seroprevalence
20%
Circulating Tumor Cell
20%
DNA Damage Response
20%
Cancer of Unknown Primary Origin
20%
Writing
20%
Hepatitis E Virus
20%
Drug Megadose
20%
Cytotoxic T-Cell
18%
Arm
17%
Cisplatin
17%
Targeted Therapy
16%
Clinical Trial
16%
Virus Infection
16%
Biopsy Technique
15%
Squamous Cell Carcinoma
15%
Ciprofloxacin
15%
Periodic Medical Examination
15%
Health Care Cost
15%
Adolescence
15%
Immunity
15%
Programmed Death-Ligand 1
15%
Surgery
15%
Progression Free Survival
14%
Melanoma Cell
14%
Keyphrases
Overall Survival
71%
Metastatic Melanoma
62%
Haiti
52%
Lipopolysaccharide
46%
Tumor
45%
Advanced Melanoma
42%
Pembrolizumab
41%
Francisella Tularensis
41%
Melanoma
40%
Confidence Interval
38%
Multiple Myeloma
36%
Hepatitis E Virus
31%
Peacekeepers
31%
Meta-analysis
31%
United Nations Missions
31%
Complete Remission
30%
Complete Response
29%
Escherichia Coli
28%
Bladder Cancer
28%
Tularemia
27%
In Cancer
27%
Radiotherapy
26%
Live Vaccine Strain
26%
Ipilimumab
25%
High Dose
24%
Chemotherapy
23%
Phase II Trial
23%
Hazard Ratio
23%
Bladder
23%
Phase I Study
23%
Genetic Modification
22%
Programmed Death-ligand 1 (PD-L1)
22%
Radiation Therapy
21%
Hepatitis E Virus Infection
20%
Creative Writing
20%
Acute Myeloid Leukemia
20%
Rituximab
20%
Patients with Cancer
20%
Survival Outcomes
19%
Median Overall Survival
19%
Monoclonal Antibody
18%
Ciprofloxacin
18%
WEE1
18%
National Cancer Institute
18%
Immunotherapeutics
18%
AIDS/HIV
17%
Temozolomide
17%
Older Men
17%
Targeted Therapy
17%
Interferon-α (IFN-α)
15%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Melanoma
99%
Neoplasm
76%
Overall Survival
65%
Immunotherapy
54%
Metastatic Melanoma
45%
Pembrolizumab
41%
Diseases
38%
Ipilimumab
34%
Bladder Cancer
29%
Clinical Trial
28%
Remission
22%
Multiple Myeloma
20%
Syndrome
20%
Rituximab
20%
Protein Tyrosine Kinase Inhibitor
19%
Progression Free Survival
18%
Protein Tyrosine Kinase
18%
Cisplatin
17%
Chemotherapy
17%
Infection
16%
Interleukin 2
16%
Cutaneous Melanoma
15%
Adverse Event
14%
Temozolomide
13%
Phase II Trials
13%
Renal Cell Carcinoma
13%
Disease
11%
Nivolumab
11%
Randomized Clinical Trial
11%
Retrospective Study
11%
Biological Marker
11%
Vaccine Development
10%
Diabetes Mellitus
10%
Phosphatase
10%
Tensin
10%
Tonsillitis
10%
Saprotroph
10%
Tolerability
10%
Antitumor Activity
10%
Monotherapy
10%
Imatinib
10%
Rheumatoid Arthritis
10%
Drug Administration
10%
Cimetidine
10%
Metastatic Uvea Melanoma
10%
Beta Adrenergic Receptor Blocking Agent
10%
Sepsis
10%
Chronic Lymphatic Leukemia
10%
Cemiplimab
10%
